New study finds that use of Blue Light Cystoscopy after BCG induction increases the detection of BCG-refractory Bladder Cancer tumors

**Photocure, The Bladder Cancer Company, announces a new study on the early use of Blue Light Cystoscopy (BLC®) after BCG induction for high risk non-muscle invasive bladder cancer (NMIBC).** The objective of the trial was to compare detection rates of BCG refractory tumors between the use of white light and blue light cystoscopy. The study was designed as a single center, single-arm retrospective study, including 136 patients with high-risk non-muscle-invasive bladder cancer diagnosed from January 2017 to January 2021. All patients underwent initial BLC TURBT* and restaging TURBT if needed, followed by full-dose BCG. Within 8 weeks following induction, all patients had both white light and blue light cystoscopy TURBT to assess the presence of bladder cancer with the following results: Bladder cancer was diagnosed in 33 out of 136 patients (24%). In 16 of the 33 patients bladder tumors were only detected with BLC. In addition, 18 patients had concomitant carcinoma in situ of which 12 cases (67%) were detected solely by BLC. The authors conclude that systematic use of BLC after BCG induction increases the detection of BCG-refractory tumors and leads to significant modification in the treatment of high-risk NMIBC. Read the full paper here: https://pubmed.ncbi.nlm.nih.gov/34107773/ *TURBT: trans-urethral resection of bladder tumors